International Corporate Responsibility Series 2:375-391 (2005)
AbstractMost major pharmaceutical companies have corporate social responsibility policies that pledge their commitment to improving the health and quality of life of people around the world. Yet these same companies also have difficulty in ensuring that developing countries have access to affordable medications. In the late 1990s, Brazil engaged in a heated battle with large US-backed multinational pharmaceutical companies. Brazil was facing a growing HIV epidemic and was determined to provide treatment to those in need. This required massive price reductions on HIV medications. Although met with resistance, Brazil’s campaign eventually resulted in the negotiation of significant price reductions. Our study examines how Brazil was able to secure these price concessions. We conclude that corporate social responsibility initiatives must be viewed as a dynamic interaction between multiple actors. Our study highlights the importance of governmental action, in both the national and international forums, to negotiate pro-actively with companies to ensure that CSR commitments are met
Similar books and articles
The HIV/AIDS crisis and corporate moral responsibility in the light of the Levinasian notions of proximity and the third.Conceição Soares - 2007 - Business Ethics, the Environment and Responsibility 16 (3):278–285.
The Corporate Social Responsibility of The Pharmaceutical Industry: Idealism Without Illusion and Realism Without Resignation.Klaus M. Leisinger - 2005 - Business Ethics Quarterly 15 (4):577-594.
Pharmaceutical Companies vs. the State: Who Is Responsible for Post-Trial Provision of Drugs in Brazil?Daniel Wei L. Wang & Octavio Luiz Motta Ferraz - 2012 - Journal of Law, Medicine and Ethics 40 (2):188-196.
Pharmaceutical companies and access to medicines – social integration and ethical CSR resolution of a global public choice problem.Onyeka K. Osuji & Okechukwu Timothy Umahi - 2012 - Journal of Global Ethics 8 (2-3):139-167.
Human Rights Responsibilities of Pharmaceutical Companies in Relation to Access to Medicines.Joo-Young Lee & Paul Hunt - 2012 - Journal of Law, Medicine and Ethics 40 (2):220-233.
Mining, corporate social responsibility and the "community": The case of Rio tinto, Richards Bay minerals and the mbonambi. [REVIEW]Paul Kapelus - 2002 - Journal of Business Ethics 39 (3):275 - 296.
In the high court of south Africa, case no. 4138/98: The global politics of access to low-cost AIDS drugs in poor countries. [REVIEW]David Barnard - 2002 - Kennedy Institute of Ethics Journal 12 (2):159-174.
Drivers of Change: A Multiple-Case Study on the Process of Institutionalization of Corporate Responsibility Among Three Multinational Companies. [REVIEW]Ulf Henning Richter - 2011 - Journal of Business Ethics 102 (2):261-279.
Pharmaceutical Companies and Global Lack of Access to Medicines: Strengthening Accountability under the Right to Health.Anand Grover, Brian Citro, Mihir Mankad & Fiona Lander - 2012 - Journal of Law, Medicine and Ethics 40 (2):234-250.
Added to PP
Historical graph of downloads
Citations of this work
Strategic Corporate Social Responsibility and Orphan Drug Development: Insights from the US and the EU Biopharmaceutical Industry. [REVIEW]Olga Bruyaka, Hanko K. Zeitzmann, Isabelle Chalamon, Richard E. Wokutch & Pooja Thakur - 2013 - Journal of Business Ethics 117 (1):45-65.
Pledging Patent Rights for Fighting Against the COVID-19: From the Ethical and Efficiency Perspective.Xiaodong Yuan & Xiaotao Li - 2022 - Journal of Business Ethics 179 (3):683-696.
Robert Merges: Justifying intellectual property: Harvard UP, Cambridge, MA, 2011, xiv+402 pp, ISBN 9780674049482. [REVIEW]Gordon Hull - 2012 - Ethics and Information Technology 14 (2):169-177.
References found in this work
No references found.